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The rapid expansion of diagnostic technologies in general and of the genome-wide association 
studies method in particular brings us closer to the understanding of the etiopathogenetic 
fundamentals of endogenous mental disorders. The amount of accumulated experience in 
genome-wide association studies allows one to assess the importance of specific genetic 
markers in the development of the diseases of interest. The introduction of screening systems 
and the assessment of disease prognosis is yet to be implemented, due to conceptual and 
methodological contradictions. The present review aims at analyzing the current progress 
in the field of genetic studies of schizophrenia spectrum disorders. The prospects and 
limitations of existing methods and the obstacles to the efficient translational application of 
the achievements of GWAS and candidate gene studies are discussed. Along with the still poor 
understanding of the etiology and pathogenesis of schizophrenia spectrum disorders, such 
issues as the ongoing debate regarding the correct classification, as well as the large degree of 
symptom heterogeneity within this group of conditions, remain a cornerstone in biological 
research. A more accurate approach to phenotyping, including the application of deep 
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phenotyping techniques, is required to form more homogenous samples for future genome-
wide association and candidate gene studies of schizophrenia spectrum disorders.
Keywords: schizophrenia, genetic marker, single nucleotide polymorphism, genome-wide 
association study, phenotyping.
Introduction
The biopsychosocial paradigm is the basis of the modern understanding of endoge-
nous mental disorders. Notably, all three components of this concept seem to be equally 
valued. In the social aspect, the burden of schizophrenia spectrum disorders is estimated 
to be up to 0.5 % of country‘s GDP [1]. The prevalence of this group of disorders appears 
to be relatively stable over time and varies insignificantly by region (1.45 %, 0.5 %, 1.6 % 
respectively) [2]. According to epidemiological data across Russian Federation, schizo-
phrenia cases constitute 16 % of all the individuals suffering from mental diseases and 40-
50 % of inpatients. The morbidity in Russia has been estimated as 6.5 per 100 thousands 
per year or about 9.5 thousand first-time registered cases annually. The number of people 
receiving psychiatric treatment is 467.1 thousand or 319.3 per 100 thousand [3]. Disabi-
lity is observed in about 60 % of patients diagnosed with schizophrenia, while 90 % have 
unstable labor force adaptation. The socio-economic burden of schizophrenia (according 
to the 2009 calculations) in Russia amounts to 196.7 billion rubles per year, 90 % of which 
is cost of accommodation of patients in clinics and medical facilities [1].
Despite the high socio-economic costs of schizophrenia spectrum disorders, efficient 
treatment for this group of disorders is still lacking. It is economically important that 
the medication for the treatment of schizophrenia are included in the index of vital and 
essential drugs [4] and therefore are part of the government budget expenses. It is worth 
noting that the etiotropic treatment for the schizophrenia spectrum disorders has not 
been developed and an introduction of anti-psychotic drugs into the clinical practice has 
not hastened a solution for the full curability problem. Moreover, large-scale studies of 
the efficiency of anti-psychotic drugs have shown high rates of treatment resistance [5; 6].
The etiology of the schizophrenia spectrum disorders is not well established yet. Se-
veral hypotheses of the etiogenesis of these diseases exist simultaneously. The majority of 
those can be narrowed down to the imbalance of neuromediators in the nervous system, 
i.e. dopamine, serotonin, noradrenaline and GABA [7–9]. Despite the lack of full un-
derstanding of the etiology and pathogenesis of schizophrenia spectrum disorders, the 
multifactorial nature of these disorders remains the most widely accepted concept, i.e. that 
taking account of the contribution of genetic and environmental factors into disease risk. 
A meta-analysis of twelve twin studies has demonstrated high heritability of schizophre-
nia spectrum disorders (estimated at 81 %) [10], which supports the dominant position 
of genetic factors in determining the risk for this group of disorders. At the same time, so 
far, there have been no valid techniques allowing to assess the risk of developing schizo-
phrenia in an individual by means of genetic analysis. This problem can be most probably 
explained by the following range of reasons: the lack of unified methodology of genetic 
studies, the lack of unified criteria for diagnosis, and the pathogenetic heterogeneity of 
this group of disorders. 
This review aims at analyzing the existing conceptual and methodological problems 
which stand in the way of the implementation of genetic testing into the diagnosis of schi-
zophrenia, as well as possible solutions to these problems. 
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Methodological issues in genetic studies of schizophrenia spectrum 
disorders
No monogenic forms of schizophrenia spectrum disorders have been described to 
date [11]. The input of genetic factors into the development of these disorders is attribu-
table to a multitude of genetic markers, each of those potentially increasing the risk of 
disease. Around 8000 polymorphisms have been associated with schizophrenia spectrum 
disorders in case-control studies [12]. However, it is too early to draw definite conclusions 
concerning the association of all these genetic markers with the risk of disease. First, the 
majority of associations have been implicated in studies with limited sample size and in 
specific populations. Second, quite a few of the findings have not been replicated in diffe-
rent samples. 
The active implementation of Genome-wide association studies (GWAS) has enabled 
the analysis of a large number of genetic markers in large-scale patient and control samp-
les. However, the markers identified using genome-wide studies can only explain up to 
25 % of the genetic variance in morbidity risk [13]. Besides, a significant number of these 
genetic markers lie outside candidate-gene loci, and their implication for disease patho-
genesis is not entirely clear. An important feature of GWAS is stringent criteria of signi-
ficance for the associated polymorphisms: an association is only considered significant 
if p-value is smaller than 5*10–8 [14]. Such stringent selection criteria inevitably lead to 
false-negative results.
It is also of note that neither GWAS nor candidate-gene studies take into account 
the possible contribution of chromosome mutations: genomic and autosomal aneuploidy, 
gene inversion and conversion, as well as copy number variation. At the same time, chro-
mosome 1 and 18 mosaic aneuploidy have been implicated as associated with schizophre-
nia in a few postmortem cases [15; 16]. Also 22q11DS syndrome, characterized, in the 
majority of cases, by an inborn loss of 3 million base pairs of the long arm of chromosome 
22 (22q11.2), has been accepted as a model of ultra-high risk of schizophrenic psychosis 
for research into environmental predictors of the disease [17].
Populational differences also represent a significant issue for valid determination of 
genetic predisposition to schizophrenia spectrum disorders. Some genetic markers asso-
ciated with increased risk of schizophrenia in certain populations, do not demonstrate a 
similar asociation in other populations [18]. This can be attributed, in the first place, to 
the difference in prevalence of genetic markers across various populations subject to the 
conditions of their habitat, e.g. the polymorphism rs1042522, which regulates body tem-
perature and enables representatives of some asian nations to withstand cold winters [19]. 
Some authors believe that genetic polymorphisms associated with risk of schizophre-
nia can also be subject to natural selection — e.g. polymorphisms of the genes CREB1, 
SLC39A8, ZNF323 и SLC6A4 [20–22]. 
Another possible reason of the populational differences in the prevalence of schi-
zophrenia-associated polymorphisms in the population is the presence in the history of 
some nations of the so-called «bottlenecks»: time periods when a significant part of the 
population perished, and only the remaining minority determined the genotype of the 
ancestry [23]. Therefore, the populational affiliation of the individuals is an important 
parameter which has to be accounted for in studies dedicated to the search of genetic 
markers associated with schizophrenia. 
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Thus, the methodological issues in the search for genetic factors determining risk of 
schizophrenia spectrum disorders can be narrowed down to the following:
1. The presence of a wide range of candidate genes whose association with 
schizophrenia has been implicated in local populations and has not been 
consistently replicated in other samples. 
2. Stringent criteria imposed by GWAS to the selection of genetic markers associated 
with conditions of interest.
3. The lack of account of populational differences in the frequency of alleles serving 
as genetic markers in schizophrenia spectrum disorders. 
Issues related to the consistency of diagnostic criteria for schizophrenia 
spectrum disorders
A crucial issue in the interpretation of the results of genetic studies is the fundamen-
tal controversy regarding the clinical criteria of the diagnosis of schizophrenia which still 
exists among research groups. The justification of the inclusion of symptoms and syn-
dromes into one nosological form of mental disorders or the other has been a matter of 
ongoing debate in clinical psychiatry. The diagnosis is made according to one of the ac-
cepted international classifications — ICD-10 [24] or DSM-5 [25]. The inclusion criteria 
of the majority of studies focusing on the identification of genetic factors associated with 
schizophrenia require that the patient’s condition matches F2 section of ICD-10, while the 
specification of those conditions is missing. At the same time, this section includes a wide 
spectrum of discreet disorders, differing significantly in the characteristics of their clinical 
course and presentation. An illustrative example of the controversy between the classifica-
tions is the putative position of catatonic symptoms. While the ICD-10 F2 section inclu-
des the category of catatonic schizophrenia (F20.2), in DSM-5, its symptoms constitute 
a separate dimension which is viewed as not specific to schizophrenia [26]. It has been 
estimated the the pathogenesis of catatonia lies in specific neurobiological and neuroim-
munological mechanisms different from those in other forms of mental disorders [27; 28]. 
Сonsequently, one can assume that these notions could also be true for a wide spectrum of 
affective (depressive and manic) disorders which fall under F 20.4 — post-schizophrenic 
depression — and F25 — schizoaffective disorder — categories. Conditions matching the 
above mentioned ICD codes are characterised by the prevalence in their clinical presenta-
tion of mood disorders, while schizophrenia symptoms become secondary and fade into 
insignificance. A different diagnostic dilemma consists in the fact that Schneider’s first 
rank symptoms such as voice echo, thought detachment, and intra-proective hearing per-
ceptional deception, which are obligatory for paranoid schizophrenia (F20) are not pre-
sent in simple schizophrenia and pseudo-neurotic and pseudopsychopathic latent schi-
zophrenia (coded as F21.3 and 21.4, respectively). It would be reasonable to assume that 
the development of the above mentioned clinical symptoms is determined by different 
underlying pathophysiological abnormalities. Therefore, orienting on ID criteria alone in 
patient enrollment can lead to the formation of a highly heterogenous sample. 
The data obtained in fundamental (non-clinical) studies in the field on neurosciences 
confirm the impossibility to directly match ICD and DSM-defined diagnoses with labora-
tory data [29]. Against the background of the absence of direct biological associations bet-
ween various clinical subtypes manifesting with psychotic symptoms as defined by ICD 
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or DSM criteria, suggestions to reassess Kraepelin’s paradigm appear quite reasonable [30; 
31]. 
In order to overcome the conceptional gap between the widely accepted classifica-
tions, NIMH (USA) initiated the introduction of the RDoC project which represents a 
fundamentally new approach to research into psychopathology and which suggests the 
shifting away from traditional nosologic categories [32]. The basic objective of this project 
lies in the search of etiopathogenetic predictors of mental disorders in order to establish 
novel therapeutic methods. To do so, authors have established a matrix of domains (basic 
psychopathological manifestations) which includes positive, negative, cognitive distur-
bances, a set of disturbances manifesting in the social sphere, as well as activating and 
modulating symptom sets. It has been suggested to trace the whole chain of processes for 
each domain to construct — starting with behavioral manifestations and down to genetic 
level — for each of the domains. However, at present, the project is still at initial stages of 
implementation [29].
Based on provided data, the following issues related to the consistency of diagnostic 
criteria for schizophrenia spectrum disorders, could be outlined:
1. The absence of a unitary set of criteria for the diagnosis of schizophrenia based on 
the constellation of symptoms.
2. The controversy that still exists between widely accepted disease classifications 
with regard to the nosological differences of various mental disorders 
3. The lack of account of the heterogeneity of the etiopathogenesis of schizophrenia 
spectrum disorders and comorbid mental pathology in genetic studies.
Discussion
The inconsistency of the currently existing approach to the search for genetic markers 
of schizophrenia spectrum disorders — i.e. the one taking little account of subgrouping 
these disorders or of the pathophysiological processes which may be specific to distinct 
disorders, — has been supported by the data indicating the association of different clinical 
manifestations of the disorders with particular genetic markers [13]. For instance, a few 
studies have associated their genetic findings only with certain forms of schizophrenia 
[33], while other studies, conversely, linked these markers to varying disorders [34]. 
Studies involving a detailed description of clinical characteristics and the specifica-
tion of clinical and genetic associations are few and are largely focused on the studies of 
candidate genes determining particular symptoms. For example, the 5-HTTLPR poly-
morphism of the SLC6A4 gene has been associated with impaired mimic emotion rec-
ognition in schizophrenia, but not with cognitive disturbances, the severity of positive 
symptoms or premorbid personality features [35]. The polymorphisms of the BDNF gene 
and their association with symptoms have also been thoroughly studied: the 66Met allele 
of BDNF has been associated with thought insertion, passivity delusions and verbal hal-
lucinations [36]. Besides, it has been estimated that BDNF gene polymorphisms are asso-
ciated not only with schizophrenia, but also with a range of other disorders characterized 
by similar symptoms [37; 38]. 
Apart from that, an illustration of the possible reasons for lack of clarity in the in-
terpretation of GWAS results, as mentioned before, is the attribution of catatonic syn-
drome to schizophrenia spectrum disorders only, with little account of the course and 
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stage of disease in which patients manifesting with catatonic phenomena were assessed. 
It has been shown that the neuronal pathways involved in the development of psychomo-
tor disturbances typical of acute catatonia are different from those determining paranoid 
or pseudoneurotic symptoms in other forms of schizophrenia spectrum disorders [39]. 
Special psychomotor phenomena constituting the catatonic syndrome may represent the 
interaction of orbitofrontal cortex with dorsolateral prefrontal cortex and the premotor 
loop, with specific alterations in the neurotransmitter components: decreased GABA-A 
receptor activity (in the orbitofrontal cortex), decreased D2 activity in corpus striatum, 
alterations in NMDA glutamatergic system (in the parietal cortex) and elevated 5HT-1A 
receptor activity [40]. 
Data regarding the clinical significance of the identification of genetic markers of 
catatonia is limited, and its interpretation is a matter of debate. Zhilyaeva et al. [41] as-
sessed 150  patients presenting with signs of catatonia using PANSS, SANS and CDSS 
scales. The conceptual approach to the evaluation of mental state in such a limited set of 
psychometric tools in this work represented the “pyramidical model of schizophrenia” 
[42], according to which, the catatonic syndrome, as a form of schizophrenia, lies at a 
nominal edge of a pyramid formed by negative and positive poles of the PANSS subscales 
(including negative, positive, cognitive disturbances, manifestations of depression and 
agitation). The results of the study have demonstrated a robust difference in the severity 
of catatonic symptoms as assessed with PANSS: in the study group (MTHFR 677C>T car-
riers), catatonic symptoms were significantly more severe than in the comparison group 
(MTHFR 677СС carriers). Authors conclude that the genetic testing for the described 
marker could be used in the diagnosis of the risk of catatonic syndrome as a predictor of 
unfavorable course of schizophrenia. However, other studies have indicated a relatively 
favorable course of schizophrenia even after several catatonic attacks, i.e. a steady remis-
sion and the maintenance of social functioning [43]. Therefore, the evaluation of the sig-
nificance of particular polymorphisms remains a matter of future studies, which would 
require account f the maximum possible number of mental phenomena.
Conclusion
The technological progress of laboratory diagnostics has sufficiently accelerated the 
understanding of causes and mechanisms of mental disorders, and first of all, schizophre-
nia spectrum disorders. To date, it has been estimated that the development of these dis-
orders is subject to several brain systems operating at the level of neuron formation [44], 
neurotransmitter system functioning, cell oxidation and metabolism, and ion channel 
functioning. The direct involvement of the immune system in the pathogenesis of schizo-
phrenia has been demonstrated as well [45]. All these abnormalities are «coded» in more 
than 8000 genes. Genetic markers found in genome-wide studies can only explain a small 
percent of genetic causes of schizophrenia spectrum disorders. The problems of practi-
cal implementation of data concerning the genetic foundation of schizophrenia spectrum 
disorders may lie in the lack of current understanding of the etiology and pathogenesis of 
these disorders and of a unified and generally accepted classification and diagnostic tools, 
as well as in the marked heterogeneity of symptoms. A possible solution to the above 
mentioned issues could be a genetic study of patients diagnosed with schizophrenia with 
account of phenotypical separation to form clinically homogenous samples. In studying 
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genetic markers, it is reasonable to rely upon both GWAS data since they have yielded ge-
netic marker data, and the analysis of polymorphisms in candidate genes whose products 
are involved in disease pathogenesis. 
Deep phenotyping has proved to be of crucial importance in performing GWAS of a 
number of other multifactorial disorders. The division of patient samples into several clin-
ical subtypes allows to determine polymorphisms directly involved in the pathogenesis of 
a certain disease. For instance, a genome-wide study of patients suffering from ischemic 
stroke with account of disease subtypes has yielded genetic markers in the PITX2 and 
ZFHX3 genes associated with cardioembolic stroke alone [46]. Earlier, these genes had 
been associated with risk of atrial fibrillation (AF) [47; 48]. While AF leads to haemo-
dynamic abnormalities and thromboembolic complications, mentioned polymorphisms 
were not associated with minor or major vessel disorders and did not reach full-genome 
significance (p < 5*10–8) in the analysis of the association with ischemic stroke without 
disease subtyping.
The phenotyping of patients suffering from schizophrenia spectrum disorders is pos-
sible with the use of common international psychometric tools allowing for a thorough 
description of clinical presentation and course of disease with further formation of dis-
crete subgroups based on the severity of impairment of various areas of mental functions 
(perception, reasoning, psychomotor function, mood, cognitive function etc.), disease 
duration, the presence of comorbid disorders, ethnic and social characteristics of subjects, 
and the effect of environmental factors.
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Стремительное развитие диагностических технологий, в  частности метода полноге-
номного поиска ассоциаций, приближает понимание этиопатогенетических основ эн-
догенных психических заболеваний. Накопленный на современном этапе опыт полно-
геномных исследований позволяет оценить значимость тех или иных генетических 
маркеров в развитии указанных заболеваний. Внедрение скрининговых систем, оценка 
прогноза заболевания остаются вопросом будущего в силу конецептульно-методоло-
гических противоречий. В настоящей статье приводится анализ результатов проведен-
ных полногеномных исследований шизофрении и  дается обоснование актуальности 
глубокого фенотипирования расстройств шизофренического спектра с целью уточне-
ния результатов генетических исследований.
Ключевые слова: шизофрения, генетический маркер, однонуклеотидный полиморфизм, 
полногеномное исследование, фенотипирование.
